Lunai Share Price

Lunai Share Price

NASDAQ: LNAI | Healthcare
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Lunai Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
N/A
Volume
N/A
Average Traded
N/A

Lunai Share Price Chart

$0.00$0.00
L
Show Current Price
H

Lunai Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.71
Revenue (TTM)
$50.00M
Return On Equity (TTM)
39.47%
Profit Margin
-7120.00%
Debt to Equity
-0.04
Quarterly Earnings Growth YoY
N/A

Lunai Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026
Revenue$0.00$0.02$0.03
Net Profit-$1.80-$2.57-$2.01
Net Profit MarginN/A-12850.00%-6700.00%
Income ChangeN/A-42.78%21.79%

Lunai Annual Profit & Loss

All figures in USD

Particulars2026
Revenue$0.05
Net Profit-$3.56
Net Profit Margin-7120.00%
Income ChangeN/A

Lunai Balance Sheet

All figures in USD Million

Particulars2026
Non Current Assets7.91
Current Assets2.04
Total Assets9.94
Non Current Liabilities0.06
Current Liabilities18.91
Total Liabilities18.97
Shareholders' Equity-9.02

Lunai Cash Flow

Annually

All figures in USD Million

Particulars2026
Operating-5.29
Investing0.54
Financing6.39

Corporate Actions

Split
Ex-date: 22 May 2026

Split
Ex-date: 30 Sep 2025

About Lunai

Lunai Bioworks Inc is an AI-driven biotechnology company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or lifelong cancer remission in some of the deadliest cancers. The Group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. Its reportable segments are BioSymetrics, which derives the maximum revenue, and RENB. Geographically, the Group operates in the United States and Canada.

Lunai Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %

Lunai Share Price FAQs